+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor



Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor



General Hospital Psychiatry 34(1): 102.E13-4



This case report highlights the risk of nutritional supplements and misinformation obtained from the internet particularly for those on monamine oxdiase inhibitors (MAOIs). Despite sophisticated medical knowledge, this patient, who was taking an MOAI and complying with a tyramine-free diet, used a supplement of hydroxytryptophan that along with the MAOI appears to have precipitated mania, despite no personal or familial history of bipolar disorder.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036221786

Download citation: RISBibTeXText

PMID: 21963353

DOI: 10.1016/j.genhosppsych.2011.08.014


Related references

The effect of a monoamine oxidase inhibitor on radiation protection of 5-hydroxytryptophan. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine 14(4): 389-390, 1968

The Effect of a Monoamine Oxidase Inhibitor on Radiation Protection by 5-hydroxytryptophan. International Journal of Radiation Biology 14(4): 389-390, 1968

Potentiation of the behavioral effects of 5 hydroxytryptophan by bw 1370u87 a selective monoamine oxidase a inhibitor. Drug Development Research 25(3): 209-213, 1992

Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 100(3): 455-487, 1977

Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. I. Inhibition by a selective monoamine oxidase-B inhibitor, MD 780236. Japanese Journal of Pharmacology 41(2): 183-189, 1986

Two cases of hypomania following the addition of L-tryptophan to a monoamine oxidase inhibitor. American Journal of Psychiatry 142(12): 1487-1488, 1985

An effect of monoamine oxidase inhibitors on brain serotonin of mice in addition to that resulting from inhibition of monoamine oxidase. Journal of Neurochemistry 9: 299-306, 1962

Sr 94191 a selective inhibitor of type a monoamine oxidase with dopaminergic properties ii. biochemical characterization of monoamine oxidase inhibition. Journal of Pharmacology and Experimental Therapeutics 240(1): 251-258, 1987

A sensitive fluorometric assay of human platelet monoamine oxidase and its application to assessment of monoamine oxidase inhibitor. Chemical & Pharmaceutical Bulletin 26(11): 3471-3476, 1978

SL251131 ,3a -3-methoxymethyl-7- -3,3a,4,5-tetrahydro-1,3-oxazolo quinolin-1-one, a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B Biochemical and behavioral profile. Journal of Pharmacology & Experimental Therapeutics 310(3): 1171-1182, 2004

Relations between inhibition of cerebral monoamine oxidase in mice and the pyridoxal-5-phosphate-monoamine oxidase inhibitor pharmacological antagonism in the presence of 3,4-dihydroxyphenylalanine. Journal de Physiologie 57(4): 475-483, 1965

The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irreversible inhibitor of monoamine oxidase--II. Studies in vivo. Biochemical Pharmacology 18(5): 1021-1028, 1969

The monoamine oxidase catalyzed degradation of phenelzine-l-14C, an irreversible inhibitor of monoamine oxidase--I. Studies in vitro. Biochemical Pharmacology 18(5): 1011-1020, 1969

SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile. Journal of Pharmacology and Experimental Therapeutics 310(3): 1171-1182, 2004

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Neurobiology of Aging 36(3): 1529-1542, 2015